About The Rx Consultant

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. Our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

Founded in 1991, The Rx Consultant has subscribers throughout the United States, Canada & The United Kingdom. For 27 years, pharmacists, nurse practitioners and pharmacy technicians have relied on The Rx Consultant for accurate, unbiased updates they can trust. We are completely independent of the pharmaceutical industry and has no commercial bias.

→ Visit The Rx Consultant

Rx Blog users - Save 40% on a subscription to
The Rx Consultant

Use Promo Code RXBLOG18

→ Subscribe Now

Q: I’ve heard that SGLT2 inhibitors can cause kidney failure; should I be worried?

A: New information suggests that taking SGLT2 inhibitors over a long period of time can actually help prevent kidney disease. However, since this type of medication works in the kidney, which controls the body’s fluids, it may increase the risk of kidney damage when you first start taking it. There is a greater chance of this happening if you are dehydrated (have lower than normal body fluid), have chronic kidney disease or congestive heart failure, or use certain other medications like diuretics (eg, furosemide), angiotensin-converting enzyme (ACE) inhibitors (eg, lisinopril), angiotensin receptor blockers (ARBs; eg, losartan, valsartan), and nonsteroidal antiinflammatory drugs (NSAIDs; eg, ibuprofen, naproxen). Sometimes, you need to take a medication that increases the chance of kidney damage. It is important to discuss this possible side effect with your healthcare provider and diabetes educator. You’ll need kidney tests before starting a SGLT2 inhibitor and during treatment.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This